NASDAQ:CODX

Co-Diagnostics (CODX) Stock Forecast, Price & News

$1.07

0.00 (0.00%)

(As of 04:32 PM ET)

Compare

Today's Range: $1.06
▼
$1.11
50-Day Range: $1.04
▼
$1.64
52-Week Range: $0.98
▼
$7.13

Volume: 181,309 shs
Average Volume: 123,343 shs
Market Capitalization: $32.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Co-Diagnostics MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 414.0% Upside
$5.50 Price Target
Short Interest: Healthy
2.39% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.10
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$5,700 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.90) to ($0.79) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

256th out of 981 stocks

Surgical & Medical Instruments Industry

26th out of 98 stocks

3.2

Analyst's Opinion

Consensus Rating
Co-Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.50, Co-Diagnostics has a forecasted upside of 414.0% from its current price of $1.07.
Amount of Analyst Coverage
Co-Diagnostics has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.39% of the outstanding shares of Co-Diagnostics have been sold short.
Short Interest Ratio / Days to Cover
Co-Diagnostics has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Co-Diagnostics has recently decreased by 12.99%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Co-Diagnostics does not currently pay a dividend.
Dividend Growth
Co-Diagnostics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Co-Diagnostics has received a 67.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Infectious disease diagnostics systems", and "PCR machines" products. See details.
Environmental Sustainability
The Environmental Impact score for Co-Diagnostics is -1.10.

0.6

News and Social Media Coverage

Search Interest
2 people have searched for CODX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Co-Diagnostics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,700.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.20% of the stock of Co-Diagnostics is held by insiders.
Percentage Held by Institutions
Only 20.33% of the stock of Co-Diagnostics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Co-Diagnostics are expected to grow in the coming year, from ($0.90) to ($0.79) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Co-Diagnostics is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Co-Diagnostics is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Co-Diagnostics has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Co-Diagnostics (NASDAQ:CODX) Stock

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Receive CODX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CODX Stock News Headlines

May 18, 2023 | finance.yahoo.com

One Co-Diagnostics, Inc. (NASDAQ:CODX) Broker Just Cut Their Revenue Forecasts By 14%

May 17, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Co-Diagnostics, Inc. Raised by HC Wainwright (NASDAQ:CODX)

June 8, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Software" to Revolutionize Warfare

This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>

May 16, 2023 | americanbankingnews.com

Co-Diagnostics, Inc. (NASDAQ:CODX) to Post Q1 2024 Earnings of ($0.23) Per Share, HC Wainwright Forecasts

May 15, 2023 | msn.com

HC Wainwright & Co. Reiterates Co-Diagnostics (CODX) Neutral Recommendation

May 15, 2023 | markets.businessinsider.com

Co-Diagnostics (CODX) Receives a Hold from H.C. Wainwright

May 13, 2023 | americanbankingnews.com

Analyzing Calmare Therapeutics (OTCMKTS:CTTC) & Co-Diagnostics (NASDAQ:CODX)

May 11, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates

June 8, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Software" to Revolutionize Warfare

May 11, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. Reports First Quarter 2023 Financial Results

May 10, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Co-Diagnostics's earnings

May 9, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. to Host Booth at Senior Living Executive Conference in New Orleans, LA

May 5, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. Announces First Quarter 2023 Earnings Release Date and Webcast

April 26, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. to Host Booth at 67th Annual CARPHA Conference April 27-29

April 16, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. (CODX)

April 13, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. to Host Booth at ECCMID 2023 April 15-18 in Copenhagen, Denmark

March 25, 2023 | americanbankingnews.com

Q1 2023 Earnings Forecast for Co-Diagnostics, Inc. (NASDAQ:CODX) Issued By Litchfield Hills Research

March 23, 2023 | finance.yahoo.com

Co-Diagnostics (NASDAQ:CODX shareholders incur further losses as stock declines 45% this week, taking three-year losses to 83%

March 22, 2023 | americanbankingnews.com

HC Wainwright Comments on Co-Diagnostics, Inc.'s Q1 2023 Earnings (NASDAQ:CODX)

March 21, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. to CEO to Deliver Keynote Address at 2023 MarketsandMarkets Conference in London, England

March 21, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2022 Earnings Call Transcript

March 17, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. to Host Booth at 10th Gene Quantification Event in Munich, Germany, March 20-22

March 16, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates

March 16, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. Reports Full Year 2022 Financial Results

March 9, 2023 | finance.yahoo.com

CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST

March 2, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. to Present and Host Booth at TRI-CON in San Diego, CA, March 6-8

February 28, 2023 | finance.yahoo.com

Co-Diagnostics, Inc. to Host Booth at 89th Annual AMCA Conference in Reno, NV on Feb 28-March 3

See More Headlines

CODX Price History

30 days | 90 days | 365 days | Advanced Chart

CODX Company Calendar

Last Earnings: 3/16/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CODX
CUSIP: N/A
CIK: 1692415
Web: www.codiagnostics.com
Phone: (801) 438-1036
Fax: N/A
Employees: 145
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.50
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +409.3%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,240,000.00
Net Margins: -261.57%
Pretax Margin: -329.67%
Return on Equity: -16.66%
Return on Assets: -15.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 23.80
Quick Ratio: 22.33

Sales & Book Value

Annual Sales: $34.22 million
Price / Sales: 0.96
Cash Flow: $0.27 per share
Price / Cash Flow: 3.96
Book Value: $3.70 per share
Price / Book: 0.29

Miscellaneous

Outstanding Shares: 30,260,000
Free Float: 29,901,000
Market Cap: $32.68 million
Optionable: Not Optionable
Beta: -0.90

Key Executives

Mr. Dwight H. Egan (Age 70)
Chairman, CEO & Pres
Comp: $512.39k

Mr. Brian L. Brown CPA (Age 47)
CFO & Company Sec.
Comp: $387.52k

Dr. Brent C. Satterfield Ph.D. (Age 46)
Co-Founder & Member of Scientific Advisory Board

Mr. Dan Bohrer CPA
VP of Fin. & Accounting

Dr. Mark Poritz Ph.D.
Chief Scientific Officer

Mr. Andrew Benson
Head of Investor Relations

Mr. Reed L. Benson (Age 75)
Gen. Counsel

Dr. Mayuranki Almaula
Sr. VP of Overseas Operations & Strategic Alliances

Mr. Cameron Gundry
Head of Commercialization LATAM/EUR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CODX Stock - Frequently Asked Questions

Should I buy or sell Co-Diagnostics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CODX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CODX, but not buy additional shares or sell existing shares.
View CODX analyst ratings or view top-rated stocks.
What is Co-Diagnostics' stock price forecast for 2023?: 3 brokerages have issued 1-year price objectives for Co-Diagnostics' stock. Their CODX share price forecasts range from $5.00 to $6.00. On average, they expect the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 409.3% from the stock's current price.
View analysts price targets for CODX or view top-rated stocks among Wall Street analysts.
How have CODX shares performed in 2023?: Co-Diagnostics' stock was trading at $2.52 at the beginning of 2023. Since then, CODX stock has decreased by 57.1% and is now trading at $1.08.
View the best growth stocks for 2023 here.
Are investors shorting Co-Diagnostics?: Co-Diagnostics saw a drop in short interest in May. As of May 15th, there was short interest totaling 723,400 shares, a drop of 13.0% from the April 30th total of 831,400 shares. Based on an average daily trading volume, of 136,700 shares, the days-to-cover ratio is currently 5.3 days.
View Co-Diagnostics' Short Interest.
When is Co-Diagnostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our CODX earnings forecast.
How were Co-Diagnostics' earnings last quarter?: Co-Diagnostics, Inc. (NASDAQ:CODX) announced its quarterly earnings results on Thursday, March, 16th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.17. The company earned $1.40 million during the quarter, compared to analyst estimates of $5.50 million. Co-Diagnostics had a negative net margin of 261.57% and a negative trailing twelve-month return on equity of 16.66%.
What ETFs hold Co-Diagnostics' stock?: ETFs with the largest weight of Co-Diagnostics (NASDAQ:CODX) stock in their portfolio include First Trust Dow Jones Select Microcap Index Fund (FDM).ETFMG Treatments Testing and Advancements ETF (GERM).
What other stocks do shareholders of Co-Diagnostics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

When did Co-Diagnostics IPO?: (CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.
What is Co-Diagnostics' stock symbol?: Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."
Who are Co-Diagnostics' major shareholders?: Co-Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.62%), American Century Companies Inc. (0.72%), Bank of New York Mellon Corp (0.47%), Dimensional Fund Advisors LP (0.14%), Susquehanna International Group LLP (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Brian Lee Brown, Dwight H Egan, Eugene Durenard, Reed L Benson and Richard S Serbin.
View institutional ownership trends.
How do I buy shares of Co-Diagnostics?: Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Co-Diagnostics' stock price today?: One share of CODX stock can currently be purchased for approximately $1.08.
How much money does Co-Diagnostics make?: Co-Diagnostics (NASDAQ:CODX) has a market capitalization of $32.68 million and generates $34.22 million in revenue each year. The company earns $-14,240,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.
How many employees does Co-Diagnostics have?: The company employs 145 workers across the globe.
How can I contact Co-Diagnostics?: Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The official website for the company is www.codiagnostics.com. The company can be reached via phone at (801) 438-1036 or via email at investors@codiagnostics.com.

This page (NASDAQ:CODX) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial